← Back to headlines
H.C. Wainwright Upgrades Milestone Pharmaceuticals Following China Approval
H.C. Wainwright reiterated a buy rating on Milestone Pharmaceuticals after the company received regulatory approval for its lead asset in China, signaling potential market expansion.
4 Sept, 11:32 — 4 Sept, 11:32
Sources
Showing 1 of 1 sources
Related Stories
Signet Jewelers Raises Profit Forecast After Strong Quarterly Results
45m ago
Nigeria’s Oil Regulator Threatens Permit Revocations for Idle Gas Flare Sites
1h ago
Record Travel Demand Hits Dublin Airport and Portuguese Cruise Industry
1h ago
Corporate Earnings Highlights from Wells Fargo and Goldman Sachs Conferences
1h ago